THE DEAL, AT A GLANCE

Basecamp Research

3/4 reviewed

Basecamp Research

Basecamp designs AI-made medicines using biological data and DNA-writing methods for cell and gene therapies.

Basecamp announced a $140M Series C financing on September 23, 2026; valuation was not disclosed.

01What it doesBasecamp designs AI-made medicines using biological data and DNA-writing methods for cell and gene therapies.Source-grounded · automated review · Explore ↗

Checked 2026-10-04 · Review due 2026-10-11

Read supporting source ↗

The company combines frontier AI…

02Who is involvedBacked by develop next-generation biological models</strong>, NVIDIA, Menlo Ventures’ Anthology Fund, NATO Innovation FundFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

03What happenedBasecamp announced a $140M Series C financing on September 23, 2026; valuation was not disclosed.Source-grounded · automated review · Explore ↗

Checked 2026-10-04 · Review due 2026-10-11

Read supporting source ↗

Basecamp Research announced $140M in…

04Why it mattersThe round supports moving AI-designed therapies toward clinical development, starting with in-body cell therapy.Interpretation · Explore ↗

Checked 2026-10-04 · Review due 2026-10-11

Read supporting source ↗

announced a $140M Series C…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

Basecamp Research · Financing Record

Explore source-linked visual explanations for Basecamp Research. Unsupported claims are withheld while source review continues.

Record 12703 · Recorded date: 2026-09-23